Published in Proc Natl Acad Sci U S A on February 12, 2010
In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol (2011) 2.69
Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer (2013) 1.87
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol (2014) 1.23
A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med (2011) 1.17
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood (2010) 1.04
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med (2012) 1.04
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol (2011) 1.02
Development and validation of an automated high-throughput system for zebrafish in vivo screenings. PLoS One (2012) 1.01
Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discov Today (2012) 0.80
Discriminating different cancer cells using a zebrafish in vivo assay. Cancers (Basel) (2011) 0.78
The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. PLoS One (2014) 0.77
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun (2015) 0.77
Anticancer drugs: A double strike at kinases. Nat Rev Drug Discov (2010) 0.76
Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res (2010) 0.76
In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis. PLoS One (2014) 0.75
Pericyte-targeting drug delivery and tissue engineering. Int J Nanomedicine (2016) 0.75
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Curr Med Chem (2011) 0.75
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest (2017) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Molecular regulation of vessel maturation. Nat Med (2003) 11.74
In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol (2002) 11.62
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 6.53
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol (2006) 4.84
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell (1999) 4.55
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24
Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res (2001) 4.20
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 3.92
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest (2003) 3.31
Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 2.82
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Pericytes and vascular stability. Exp Cell Res (2005) 2.39
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest (2002) 2.26
In vitro three dimensional collagen matrix models of endothelial lumen formation during vasculogenesis and angiogenesis. Methods Enzymol (2008) 2.16
Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res (2002) 2.11
Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 2.02
Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res (2005) 1.64
Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest (2002) 1.47
Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis (1999) 1.38
Tumor microenvironment and angiogenesis. Front Biosci (2008) 1.38
Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine. J Surg Res (2006) 1.28
Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene (1996) 1.25
The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol (2002) 1.06
Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res (2003) 1.04
Common bile duct injection as a novel method for establishing red fluorescent protein (RFP)-expressing human pancreatic cancer in nude mice. JOP (2006) 0.93
Yaf2 inhibits caspase 8-mediated apoptosis and regulates cell survival during zebrafish embryogenesis. J Biol Chem (2006) 0.89
Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr Eye Res (2003) 0.85
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Role of integrins in cell invasion and migration. Nat Rev Cancer (2002) 7.64
Spatiotemporal dynamics of RhoA activity in migrating cells. Nature (2006) 6.84
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005) 4.08
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
Structural basis for the spectral difference in luciferase bioluminescence. Nature (2006) 3.60
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45
Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res (2006) 3.42
Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Differential regulation of cell motility and invasion by FAK. J Cell Biol (2003) 3.15
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci U S A (2003) 3.07
Dissection of synapse induction by neuroligins: effect of a neuroligin mutation associated with autism. J Biol Chem (2005) 3.06
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol (2002) 2.84
Metastases to the thyroid: a review of the literature from the last decade. Thyroid (2012) 2.83
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. Proc Natl Acad Sci U S A (2005) 2.78
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70
The Arg451Cys-neuroligin-3 mutation associated with autism reveals a defect in protein processing. J Neurosci (2004) 2.66
Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci (2002) 2.62
Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem (2005) 2.59
A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A (2002) 2.58
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A (2008) 2.55
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res (2006) 2.51
In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A (2009) 2.46
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A (2007) 2.46
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics (2011) 2.44
Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg (2008) 2.41
Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function. Cell Cycle (2008) 2.39
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem (2008) 2.35
Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle (2009) 2.28
Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg (2008) 2.27
Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models. J Am Coll Surg (2012) 2.24
Implanted hair follicle stem cells form Schwann cells that support repair of severed peripheral nerves. Proc Natl Acad Sci U S A (2005) 2.22
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res (2002) 2.11
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med (2009) 2.10
Middle Paleolithic assemblages from the Indian subcontinent before and after the Toba super-eruption. Science (2007) 2.03
Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 2.02
Nascent blood vessels in the skin arise from nestin-expressing hair-follicle cells. Proc Natl Acad Sci U S A (2004) 2.00
Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc Natl Acad Sci U S A (2003) 1.98
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol (2003) 1.93
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood (2008) 1.93
Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res (2004) 1.90
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res (2009) 1.89
Purification of pseudopodia from polarized cells reveals redistribution and activation of Rac through assembly of a CAS/Crk scaffold. J Cell Biol (2002) 1.87
Infrared multiphoton microscopy: subcellular-resolved deep tissue imaging. Curr Opin Biotechnol (2009) 1.86
VEGF-induced vascular permeability is mediated by FAK. Dev Cell (2012) 1.85
Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochim Biophys Acta (2004) 1.84
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res (2003) 1.82
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A (2004) 1.82
Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol (2010) 1.81
Tryptophan fluorescence reveals conformational changes in the acetylcholine binding protein. J Biol Chem (2002) 1.81
Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res (2009) 1.81
Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res (2009) 1.76
Tumor-selective, adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. Cell Cycle (2011) 1.76
In vivo color-coded imaging of the interaction of colon cancer cells and splenocytes in the formation of liver metastases. Cancer Res (2006) 1.76